• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·MDRX
Share

Veradigm Inc. Stocks

$ 4.75Last Updated 17.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

$ 806.69M

$ 4.75
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of f

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of MDRX is 6.41 and suggests 30.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.07.2026 16:01

Small caps last week: Papa John's doubts, Perfect goes private, LLY-AtaiBeckley deal

18.07.2026 13:01

IBM's Worst Day, SK Hynix's Record Plunge, and the "Earnings Bubble" in AI

18.07.2026 03:31

Meta Is in Talks with Anthropic to Lease Data Centers for $10 Billion — The New York Times

18.07.2026 01:33

U.S. stocks closed lower. Chipmakers had their worst week in more than a year.

18.07.2026 00:58

Adidas won the marketing battle against Nike at the World Cup. Investors took note.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026